InterMune, Inc. (NASDAQ:ITMN)

CAPS Rating: 2 out of 5

The Company is a biotech company focused on developing and commercializing innovative therapies in pulmonology and hepatology.

Recs

2
Player Avatar zzlangerhans (99.78) Submitted: 3/13/2014 10:27:45 PM : Outperform Start Price: $33.73 ITMN Score: +110.89

I suppose I could do a discounted cash flow analysis for Intermune, factoring in the probabilities of different reimbursement levels for pirfenidone in the US and potential competition from nintedanib if Boehringer reports positive data from the INPULSIS trials in May. Then again, I could just wing it and spend that time playing on the Ipad with my daughter instead. No contest, really. Based on the way I've seen this stock behave over the last seven years, I see the share price reaching at least 36 some time before the ATS conference in mid-May. My level of confidence isn't enough to get me to buy in at a share price of 33 for a potential 10% gain, but if the stock were to decline below 30 and stabilize I would likely make Intermune a small part of the zzporte portfolio.

Featured Broker Partners


Advertisement